Researchers have developed and validated a new screening test to detect pancreatic cancer in people with newly diagnosed diabetes.
The new test relies on detecting a very distinctive epigenetic marker of pancreatic cancer in the blood, the appearance of 5-hydroxymethylcytosine (5hmC) in cell-free DNA that’s isolated from a 20 mL blood specimen.
This cost-effective technology will be useful in detecting occult pancreatic cancer at an early stage in high-risk patients, which may greatly improve survival. Read more. . . .